Chemokine Therapeutics (OTC BB: CHKT) today announced that the Company is presently featured in an online interview at http://www.PRBroadcast.com. Dr. Hassan Salari, CEO of Chemokine Therapeutics, discusses recent news events, patents, and their primary innovative cancer treatment product CTCE-9908, presently in phase two trials.
